Thus, this combination of antibodies may be preferable in dual blockade VEGF/VEGFR2 treatment, while further preclinical and clinical evaluation of its efficacy and safety including such side-effects as hypertension, hemorrhage, perforation, anemia is required. The gene discussed is VEGFA; the disease is anemia (phenotype).